Aclidinium recommended for NHS use in Wales

摘要

ADULT NHS patients with chronic obstructive pulmonary disease in Wales can now be treated with aclidinium bromide (Eklira Genuair) as a maintenance bronchodilator to relieve symptoms, thanks to a recommendation by the All Wales Medicines Strategy Group. In advice ratified by the Welsh Government last week, the AWMSG also recommended that adalimumab (Humira) can be used for the treatment of adults with severe axial spondylo-arthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein or magnetic resonance imaging, or both.